readthroughSign in
Oct 2, 2026Weekly roundupUpdated

Sanofi posts SAR444881 results; adds two rilzabrutinib trials and RSV AI study

Sanofi's terminated tumor trial gained results, two new rilzabrutinib pharmacology studies were posted, and an RSV AI intervention trial was registered in China.

Four Sanofi-linked registry updates were posted between September 29 and October 2, 2026, alongside a continuing hemophilia study first posted earlier in the year.

  • SAR444881 (also known as BND-22), tested alone and in combination with pembrolizumab, cetuximab, or chemotherapy in a Phase 1/2 trial for advanced solid tumors, had results posted on 2026-09-29. The trial was terminated after enrolling advanced cancer participants with unresectable or metastatic disease who were refractory to or were not candidates for standard approved therapy1, with the company stating the stop reflected "Early discontinuation based on strategic sponsor decision not driven by any safety concerns,"1 and enrollment reached 125 participants (actual)1.
  • A Phase 1 study of rilzabrutinib (also known as SAR444671) in participants with severe renal impairment was first posted on 2026-10-01, listed as not yet recruiting. The trial is designed to assess the effect of severe RI on PK, safety, and tolerability of rilzabrutinib compared with normal renal function, in male and female participants aged from 18 to 75 years2, with an estimated enrollment of 16 participants and an estimated start date of 2026-10-09.
  • A separate Phase 1 drug-drug interaction study of rilzabrutinib was first posted on 2026-10-02, listed as recruiting. The study is a single-center, Phase-1, open-label, one-sequence, two-treatment period, cross-over, DDI study designed to investigate the effects of rilzabrutinib on the PK of digoxin and of rosuvastatin in healthy male and female participants3, with an estimated enrollment of 14 participants at a single site in Canada.
  • A new trial sponsored by Fudan University, with Sanofi as a collaborator, was first posted on 2026-10-02 and listed as not yet recruiting. The study will evaluate whether an AI-assisted primary care intervention for parents can increase RSV monoclonal antibody (mAb) uptake among infants, and to assess the cost-effectiveness and potential for implementing the intervention in routine primary care4 in China, with an estimated enrollment of 1,500 participants and an estimated start date of 2026-10-02.
  • An observational University of Texas Southwestern Medical Center study naming Sanofi as a collaborator, first posted 2026-07-09, continues recruiting children with hemophilia A. The study compares children with moderate or severe hemophilia A when treated with prophylactic extended half-life factor VIII based replacement therapy (such as Altuviiio) vs non-FVIII based replacement therapy (such as Hemlibra)5, with an estimated enrollment of 60 participants and estimated completion in May 2033.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.